[go: up one dir, main page]

PT837672E - Preparacoes e metodos para o tratamento de doencas mediadas por celulas t - Google Patents

Preparacoes e metodos para o tratamento de doencas mediadas por celulas t

Info

Publication number
PT837672E
PT837672E PT96924371T PT96924371T PT837672E PT 837672 E PT837672 E PT 837672E PT 96924371 T PT96924371 T PT 96924371T PT 96924371 T PT96924371 T PT 96924371T PT 837672 E PT837672 E PT 837672E
Authority
PT
Portugal
Prior art keywords
cells
treatment
preparations
methods
diseases mediated
Prior art date
Application number
PT96924371T
Other languages
English (en)
Inventor
Meir Shinitzky
Irun R Cohen
Dana Elias
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of PT837672E publication Critical patent/PT837672E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
PT96924371T 1995-07-05 1996-07-02 Preparacoes e metodos para o tratamento de doencas mediadas por celulas t PT837672E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases

Publications (1)

Publication Number Publication Date
PT837672E true PT837672E (pt) 2004-03-31

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96924371T PT837672E (pt) 1995-07-05 1996-07-02 Preparacoes e metodos para o tratamento de doencas mediadas por celulas t

Country Status (22)

Country Link
EP (1) EP0837672B9 (pt)
JP (2) JP4357595B2 (pt)
KR (1) KR100435040B1 (pt)
CN (1) CN1102382C (pt)
AT (1) ATE254451T1 (pt)
AU (1) AU714970B2 (pt)
CA (1) CA2226013C (pt)
CZ (1) CZ298A3 (pt)
DE (1) DE69630787T2 (pt)
DK (1) DK0837672T3 (pt)
ES (1) ES2211963T3 (pt)
HR (1) HRP960315A2 (pt)
HU (1) HU223081B1 (pt)
IL (2) IL114458A0 (pt)
MX (1) MX9800190A (pt)
NO (1) NO320363B1 (pt)
PT (1) PT837672E (pt)
SI (1) SI0837672T1 (pt)
UY (1) UY24275A1 (pt)
WO (1) WO1997002016A1 (pt)
YU (1) YU40796A (pt)
ZA (1) ZA965666B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
EP2301566B1 (en) 2002-05-21 2013-07-03 Irun R. Cohen DNA vaccines encoding heat shock proteins
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
CA2547079A1 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
US9078843B2 (en) 2005-09-22 2015-07-14 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
CN1193907A (zh) 1998-09-23
EP0837672A4 (en) 1999-01-27
HUP9802834A3 (en) 2001-08-28
HRP960315A2 (en) 1998-02-28
EP0837672A1 (en) 1998-04-29
ATE254451T1 (de) 2003-12-15
CN1102382C (zh) 2003-03-05
MX9800190A (es) 1998-04-30
AU6484496A (en) 1997-02-05
HU223081B1 (hu) 2004-03-29
HUP9802834A2 (hu) 1999-03-29
DE69630787T2 (de) 2004-10-07
JP4357595B2 (ja) 2009-11-04
JP2009242412A (ja) 2009-10-22
UY24275A1 (es) 2000-12-29
CA2226013A1 (en) 1997-01-23
NO980013L (no) 1998-02-19
WO1997002016A1 (en) 1997-01-23
EP0837672B1 (en) 2003-11-19
KR100435040B1 (ko) 2004-08-18
NO980013D0 (no) 1998-01-02
IL114458A0 (en) 1995-11-27
IL122755A0 (en) 1998-08-16
CA2226013C (en) 2012-09-18
CZ298A3 (cs) 1998-06-17
ZA965666B (en) 1997-01-27
YU40796A (sh) 1998-11-05
SI0837672T1 (en) 2004-04-30
NO320363B1 (no) 2005-11-28
EP0837672B9 (en) 2005-06-15
DE69630787D1 (de) 2003-12-24
ES2211963T3 (es) 2004-07-16
DK0837672T3 (da) 2004-03-22
IL122755A (en) 2004-07-25
JPH11508899A (ja) 1999-08-03
AU714970B2 (en) 2000-01-13
KR19990028738A (ko) 1999-04-15

Similar Documents

Publication Publication Date Title
Verstappen et al. Th17 cells in primary Sjögren's syndrome: pathogenicity and plasticity
Maizels et al. Helminths in the hygiene hypothesis: sooner or later?
PT837672E (pt) Preparacoes e metodos para o tratamento de doencas mediadas por celulas t
Gautam et al. The profile of cytokines (IL‐2, IFN‐γ, IL‐4, IL‐10, IL‐17A, and IL‐23) in active alopecia areata
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
CY1108397T1 (el) Αντι-ccr4 αντισωμα και θραυσμα αυτου
BR9907189A (pt) Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso
ES2051897T3 (es) Genes clonados que codifican proteinas de fusion ig-cd4 y su uso.
PE20050712A1 (es) Anticuerpos rg1
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
ES2154741T3 (es) Uso de agentes de union a cd23 en el tratamiento de enfermedades autoinmunes.
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ES2074268T3 (es) Vacunacion idiotipica contra el linfoma de celulas b.
PE20030473A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PT952772E (pt) Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
UY27662A1 (es) Inhibidores de la mocroglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny.
ES2053712T3 (es) Un antigeno proteico reactivo y fragmentos del mismo.
Huang et al. Clinical manual of dermatology
Chen What's new about the mechanism of methotrexate action in psoriasis?
AR027694A1 (es) Uso de la proteina mia para el tratamiento de enfermedades autoinmunes
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
HUP9901077A2 (hu) Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen